BioSpace News Archive

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to share the outcome of recent laboratory data on their PolyTope® TATX-03 antibody cocktail, which demonstrates strong neutralizing activity toward the Omicron subvariant BA.2.

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2022 financial results and business highlights.

Nanalysis Scientific Corp. announces that on Thursday, April 28, 2022 the Company will put out their fourth quarter and full year results release for year ending December 31, 2021.

Creative Medical Technology Holdings, Inc. today announced progress in developing a reproducible clinical grade product of ImmCelz®. Multiple clinical experiments were performed in which the ImmCelz® product was produced in less than 72 hours, utilizing the Company’s cell-free supercharging solution.

Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the 2022 Bloom Burton & Co. Healthcare Investment Conference to be held May 2-3, 2022.

The Clinical Research Forum (CR Forum), a non-profit membership association of top clinical research experts and thought leaders from the nation’s leading academic health centers, today announced that its top honor, the Herbert Pardes Clinical Research Excellence Award, was given to a research team from Northwestern University Feinberg School of Medicine for a groundbreaking study, Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Elligo Health Research, the largest healthcare-enabling research organization, announced they are expanding partnerships to include Peoples Rx, an Austin, Texas-based pharmacy chain.

Rise in prevalence of brucellosis and increase in awareness among people are projected to drive the global brucellosis vaccine market during the forecast period.

Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification,

According to the report, the global solitary fibrous tumor treatment market size is expected to worth around US$ 59.3 million by 2031 and is projected to expand at a CAGR of 4.5% from 2021 to 2031.